Symbiotec Pharmalab Limited IPO Price: ₹938 to ₹988 per share
IPO Dates: 24 Aug to 27 Aug, 2026
Company Overview
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products.
The company serves domestic and international markets across regulated and emerging regions.
Business Operations
With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform.
The company focuses on research-driven manufacturing, quality compliance, and sustainable production processes.
Product Focus
The company manufactures active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products.
It supports the pharmaceutical, nutraceutical, and wellness industries by providing high-quality ingredients aligned with global standards.
Manufacturing Facilities
As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities.
The facilities have a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres.
Regulatory Approvals
The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations.
Market Position
The company has established global leadership in corticosteroid and steroidal hormone APIs.
Customer Base
Symbiotec Pharmalab has long-standing relationships with domestic and international customers.
Research & Development
The company continuously invests in research and development, supported by strong technological capabilities among Indian industry peers.
The company also leverages its scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings.
Competitive Strengths
- Global leadership in corticosteroid and steroidal hormone APIs.
- Long-standing relationships with domestic and international customers.
- Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record.
- Continuous investment in research and development, supported by strong technological capabilities among Indian industry peers.
- Ability to leverage scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings.
Bidding Starts In
Symbiotec Pharmalab Limited IPO Specifics:
| IPO Date | 24 to 27 Aug, 2026 |
| Listing Date | Tue, Sep 1, 2026 |
| Face Value | ₹2 per share |
| Price Band | ₹938 to ₹988 |
| Lot Size | 15 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Employee Discount | ₹90.00 |
| Total Issue Size | 1,77,86,442 shares (agg. up to ₹1,757 Cr) |
| Fresh Issue | 15,21,261 shares (agg. up to ₹150 Cr) |
| Offer for Sale | 1,62,65,181 shares of ₹2 (agg. up to ₹1,607 Cr) |
| Share Holding Pre Issue | 6,16,81,496 shares |
| Share Holding Post Issue | 6,32,02,757 shares |
Symbiotec Pharmalab Limited IPO Timetable (Important Dates)
| Event | Date |
|---|---|
| IPO Open | Mon, Aug 24, 2026 |
| IPO Close | Thu, Aug 27, 2026 |
| Allotment | Fri, Aug 28, 2026 |
| Refund | Mon, Aug 31, 2026 |
| Credit of Shares | Mon, Aug 31, 2026 |
| Listing | Tue, Sep 1, 2026 |
Symbiotec Pharmalab Limited IPO Lot Size
Bidders have the opportunity to bid for a minimum of 15 shares, with the option to increase in multiples. The table below outlines the minimum and maximum investment thresholds for both retail investors and High Net Worth Individuals (HNIs), specifying the corresponding number of shares and amounts involved.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹14,820 |
| Retail (Max) | 13 | 195 | ₹1,92,660 |
| S-HNI (Min) | 14 | 210 | ₹2,07,480 |
| S-HNI (Max) | 67 | 1,005 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1,020 | ₹10,07,760 |
Symbiotec Pharmalab Limited IPO Reservation
| Investor Category | Shares |
|---|---|
| QIB | Not more than 50% of the Net Offer |
| Retail | Not less than 35.00% of the Net Offer |
| NII | Not less than 15% of the Net Offer |
Symbiotec Pharmalab Limited IPO Financial Information
| Particulars (₹ Cr) | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 1,780.79 | 1,579.65 | 1,294.79 |
| Total Income | 872.26 | 755.98 | 723.33 |
| Profit After Tax | 109.90 | 96.79 | 100.06 |
| EBITDA | 231.97 | 206.11 | 177.04 |
| Net Worth | 1,158.64 | 821.15 | 720.68 |
| Reserves & Surplus | 1,145.95 | 810.03 | 709.54 |
| Total Borrowing | 387.91 | 540.92 | 247.21 |
Key Performance Indicator- Symbiotec Pharmalab Limited IPO
| KPI | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| ROE | 11.19% | 12.66% |
| ROCE | 11.56% | 11.80% |
| RoNW | 9.48% | 11.79% |
| PAT Margin | 12.60% | 12.80% |
| EBITDA Margin | 26.59% | 27.26% |
| NAV | 184.69 | 150.17 |
| Price to Book Value | 5.35 | 6.58 |
| Valuation Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 17.82 | 17.39 |
| P/E (x) | 55.44 | 56.81 |
| Market Cap at Offer Price | ₹6,094Cr. | ₹6,244.43 Cr |
Prospectus Links:
Prospectus: Official documents that provide detailed information about the IPO and the company.
Symbiotec Pharmalab Limited IPO RHP
Kaashika is a social media strategist and financial content creator at Lakshmishree. She specialises in simplifying complex IPO and stock market concepts into clear, easy-to-understand content. Having created over 500+ pieces of financial content across reels, blogs, website posts and digital creatives, Kaashika helps audiences connect with the world of finance in a more accessible and engaging way.
